CTOs on the Move

Premier Research

www.premier-research.com

 
We`re out to change the course of medical science. Are you ready to rise to the challenge? Premier Research is not about being everything to everyone. Instead, our deep, focused expertise targets the therapeutic areas and indications where today`s biotech and specialty pharma pioneers are doing the most amazing work. We`re 1,000 employees strong and operate in more than 20 countries, delivering unmatched expertise, operational skills, and dedication to meeting customers` most challenging needs. Join us and meet some of the brightest minds in clinical development today — people who apply their best thinking to every project, recognizing that what they do ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Mike Irene
Chief Information Officer Profile
Brian Kachel
Executive Director, IT Operations Profile
Nathan Thompson
Chief Information Officer Profile

Similar Companies

BioMS Medical Corporation

BioMS Medical Corporation is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Physicians Eye Care Center of America

The Physicians Eye Care Center of America is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fisher Micro

Fisher Micro is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Advanced Monitored Caregiving Health

Advanced Monitored Caregiving Health is a leading provider of customized, scalable and cost-effective “real-time” patient management solutions that assist organizations serving at-risk populations or that conduct clinical trials. Its patient engagement, health monitoring and care coordination solutions have been proven in several studies published in peer-reviewed journals to improve patient outcomes and quality of care, and reduce overall healthcare costs. AMC Health is headquartered in New York City.

RaNA Therapeutics

RaNA Therapeutics is pioneering the discovery of a new class of RNA-targeted medicines that selectively activate protein expression within the body`s own cells. By targeting specific genes, RaNA`s novel drugs work epigenetically to precisely upregulate the expression of beneficial proteins in order to treat or prevent disease. The company`s leadership leverages preeminent founders and advisors in the field, and the strength of its fundamental patents, technology, and know-how that underlie the discovery and development of therapeutics that selectively activate RNA. RaNA is applying its proprietary technology to rapidly advance a pipeline of novel drugs for diverse therapeutic areas, with an initial emphasis in the fields of rare genetic disorders, inflammation, oncology, metabolic diseases and neurodegenerative diseases.